China To Offer mRNA Booster Dose For Sinovac + Sinopharm!

China is planning to offer an mRNA vaccine as a booster dose for Sinovac and Sinopharm vaccines!

Find out WHY China is switching to an mRNA vaccine!


China To Offer mRNA Booster Dose For Sinovac + Sinopharm!

On 15 July 2021, Caixin Global reported that Chinese drug regulators have completed an expert panel review of a COVID-19 mRNA vaccine that was co-developed by Fosun Pharma with BioNTech from Germany.

The booster dose is currently in the administration review stage, according to Fosun.

Fosun Pharma Chairman Wu Yifang told a shareholder’s meeting on 14 July 2021 that they plan to start domestic trial production by the end of August 2021.

The Chinese authorities plan to use the vaccine – also called COMIRNATY – as a booster dose because inactivated virus vaccines made by Sinovac and Sinopharm “demonstrated lower efficacy“.

This booster dose is likely to be offered for free to those who received vaccines made by Sinovac and Sinopharm.

China administered more than 1.46 billion vaccine doses by 18 July 2021, the vast majority of which were inactivated virus vaccines made by Sinovac and Sinopharm.

It is unknown what role Fosun Pharma played in the development in this booster dose, as they do not appear to have any expertise in developing mRNA vaccines.

It seems likely that their role is mainly to produce the COMIRNATY vaccine doses, with their “co-developed” status offering political cover to the Chinese government, which has long touted the safety and efficacy of their inactivated virus vaccines.

If China approves this mRNA booster dose, I expect the current Chinese propaganda war against Western vaccine technologies, especially the mRNA vaccine, to quickly die down.

They will now have to work hard to convince the Chinese people that mRNA vaccines are actually safe and effective…

Read more : How Chinese Vaccine Propaganda Hobbles Vaccination Efforts


Why China Plans To Offer mRNA Booster Dose

On 24 June 2021, Chinese CDC deputy director Dr. Feng Zijian told the China Central Television that antibodies from two Chinese COVID-19 vaccines are “less effective” against the Delta variant, compared to other strains.

In that interview, he declined to name the two Chinese vaccines, but the Caixin Global report appears to confirm that they are the Sinovac CoronaVac and Sinopharm BBIBP-CorV vaccines.

Sinovac itself appears to be cognisant of this limitation, and have conducting clinical research on a booster dose of their own.

But it appears that the Chinese government is not going to wait, but will instead boost protection against the Delta variant using an mRNA vaccine instead.

The BioNTech mRNA vaccine booster dose is also using the Pfizer COMIRNATY brand, so it seems likely that this booster dose is either :

  • using the existing COMIRNATY vaccine, or
  • the new vaccine version Pfizer and BioNTech are developing against the Delta variant

It seems more likely that the booster dose uses the existing COMIRNATY vaccine, because Pfizer and BioNTech are only launching clinical trials for the new vaccine version in August 2021.

Read more : Two Chinese Vaccines Less Effective Against Delta Variant


Please Support My Work!

If you would like to support my work, you can do so via bank transfer /  PayPal / credit card.

Name : Adrian Wong

Bank Transfer : CIMB 7064555917 (Swift Code : CIBBMYKL)
Credit Card / Paypal :

Thank you in advanced! ❤️


Recommended Reading

Go Back To > Health | Business | Tech ARP


Support Tech ARP!

Please support us by visiting our sponsors, participating in the Tech ARP Forums, or donating to our fund. Thank you!

Leave a ReplyCancel reply